Abstract
Cluster of differentiation 46 (CD46) is expressed at high level in CRPC and expression is further enriched upon androgen signaling inhibition (ASI) and in treatment-emergent small cell neuroendorcine prostate cancer (t-SCNC). FOR46 is a vc-MMAE antibody-drug conjugate that recognizes a tumor selective epitope of CD46. FOR46 binds to CD46 with high affinity and demonstrates anti-tumor activity in prostate cancer xenografts. A first-in-human study of safety and preliminary efficacy of FOR46 in mCRPC patients (pts) was undertaken.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
